AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01525043
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg bid
Trial: NCT00629928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00954447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, identical to Linagliptin tablet
Trial: NCT03690778
Drug: Metformin and Rosuvastatin seperately
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administration of Metformin and Rosuvastatin seperately
Trial: NCT03690778
Drug: JLP-1310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of JLP-1310
Trial: NCT03420105
Drug: Hormonotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant hormone therapy
Trial: NCT00678704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet prior to intercourse on demand
Trial: NCT01126073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will receive placebo in addition to the statin therapy. Patients will receive 1 tablet for 4 weeks, after that the dose will be increased to 2 tablets for the rest of the study period.
Trial: NCT02988908
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14
Trial: NCT02873156
Drug: E2027 matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive E2027 matched placebo capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 matched placebo will be administered orally with 240 mL (8 fluid ounces) of water.
Trial: NCT00506623
Drug: Capecitabine, Irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01202695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT04542681
Drug: Placebo - 1st Cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single SQ injection of placebo/normal saline
Trial: NCT04542681
Drug: MANP - 1st Cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg
Trial: NCT04542681
Drug: MANP - 2nd Cycle
RxNorm normalized name: CEPHALOSPORIN 2ND GENERATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single SQ injection of MANP 5 μg/kg concentration.
Trial: NCT01203345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An equal volume of 5 percent albumin solution
Trial: NCT00992550
Drug: Cigarette
RxNorm normalized name: CIGARETTE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00992550
Drug: Hookah
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01340456
Drug: Rifampicin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)
Trial: NCT00004466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01997164
Drug: REGN910-3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01997164
Drug: REGN910
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01137890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules administered in split doses at 22:00 and 09:00.
Trial: NCT00003888
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03896633
Drug: Azopt 1%
RxNorm normalized name: Azopt 1% Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azopt 1%, RLD
Trial: NCT01006395
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: yearly infusion
Trial: NCT01006395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: yearly infusion
Trial: NCT03419494
Drug: PLD
RxNorm normalized name: PLD1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD36mg/m2.d d1、d15，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
Trial: NCT03419494
Drug: DNR
RxNorm normalized name: Do Not Resuscitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNR 45mg/m2.d d1～3，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
Trial: NCT00318617
Drug: GW510516X
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03498716
Drug: Dose-dense Doxorubicin or dose-dense Epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense doxorubicin will be administered by IV, 60 mg/m\^2 every 2 weeks for a total of 4 doses.~Or~Dose-dense epirubicin will be administered by IV, (90 mg/m\^2) every 2 weeks for a total of 4 doses
Trial: NCT03498716
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered by IV, 600 mg/m\^2 every 2 weeks for 4 doses
Trial: NCT04770207
Drug: Injection of drug-eluting microspheres with multiple drugs into solid tumors
RxNorm normalized name: microspheres of human albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor
Trial: NCT00934921
Drug: Zofran®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 8 mg ODT
Trial: NCT02406651
Drug: Systemic Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
Trial: NCT01815125
Drug: PLacebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00916227
Drug: ARRY-614, p38/Tie2 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
Trial: NCT03467113
Drug: ZX008 0.2 to 0.8 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.
Trial: NCT02783833
Drug: MMV390048 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02248571
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered as combined therapy with Bevacizumab
Trial: NCT03616821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous placebo every 4 weeks beginning on Day 71 through Week 50.
Trial: NCT04233515
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical visit to a physician to assess stroke and bleeding risk and to possibly initiate OAC therapy or refer for left atrial appendage occlusion
Trial: NCT03429140
Drug: Gel-One
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an injection of Gel-One® (hyaluronan, 3 mL) 1-2 weeks after ACL surgery
Trial: NCT00437099
Drug: Omacor®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: arm 1: Omacor 1680 Arm 2: Omacor 3360
Trial: NCT00437099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01017614
Drug: Iron Sulphate
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg daily
Trial: NCT02103465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal patch
Trial: NCT02114645
Drug: 4 mg oral estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estrofem is given twice a day
Trial: NCT04145596
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
Trial: NCT00431964
Drug: azithromycin 250 mg tablets
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs
Trial: NCT00431964
Drug: placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs
Trial: NCT02108288
Drug: OPC-1085EL ophthalmic solution
RxNorm normalized name: Opcon-A Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01985789
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03509025
Drug: Jointstem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
Trial: NCT00665834
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin 20 mg from day 0 to (maximum) day 6
Trial: NCT00665834
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 20 mg from day 0 to (maximum) day 6
Trial: NCT00665834
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin 20 mg from discharge until the end of the study
Trial: NCT01722240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01516372
Drug: GEn Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GEn Tablets
Trial: NCT01518920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution
Trial: NCT03514784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin
Trial: NCT02738151
Drug: Non-insulin anti-diabetic treatment
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.
Trial: NCT00119418
Drug: TU 025 Keishi Bukuryo Gan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00153660
Drug: Celecoxib(drug)
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 100 mg bd
Trial: NCT00153660
Drug: Naproxen(drug)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg bd
Trial: NCT04138056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
Trial: NCT01928524
Drug: DOS2w Dose level 2A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
Trial: NCT01483560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 years duration
Trial: NCT02578901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered
Trial: NCT00567554
Drug: epirubicin - cyclophosphamide / docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00567554
Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03949517
Drug: 68-Ga RM2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioactive agent
Trial: NCT03949517
Drug: 68-Ga PSMA11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioactive agent
Trial: NCT01429688
Drug: Anplag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
Trial: NCT00133445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
Trial: NCT00608062
Drug: Transdermal estradiol patch
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
Trial: NCT00608062
Drug: Transdermal placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
Trial: NCT00746811
Drug: P-OM3
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 grams/day - 4 one gram capsules
Trial: NCT00746811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 grams/day - 4 one gram capsules
Trial: NCT04016714
Drug: V114
RxNorm normalized name: Pneumococcal 15-valent Conjugate Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, serotype 6B and aluminum phosphate adjuvant in each 0.5 mL dose.
Trial: NCT04016714
Drug: Prevenar 13™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
Trial: NCT04016714
Drug: Vaxelis™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 0.5 mL single dose
Trial: NCT04016714
Drug: M-M-R®II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous 0.5 mL single dose
Trial: NCT04016714
Drug: VARIVAX™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous 0.5 mL single dose
Trial: NCT01928524
Drug: DOS3w Dose level 3B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
Trial: NCT00867139
Drug: TCAD
RxNorm normalized name: Tricyclic Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
Trial: NCT00923910
Drug: Endotoxin
RxNorm normalized name: Endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified lipopolysaccharide prepared from E.Coli 0:113
Trial: NCT00833521
Drug: AMBIEN® 10 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10 mg
Trial: NCT01590173
Drug: Prednisolone and Heparin during COH for IVF
RxNorm normalized name: prednisolone and antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day and 5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test. In cases of pregnancy, prednisolone and enoxaparin were to be continued up to the 12th and 34th week, respectively
Trial: NCT00923910
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-medication
Trial: NCT01448642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo before PCI and 24 hours after PCI. Atorvastatin 40mg for 30 days
Trial: NCT00425620
Drug: SinuNase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavage
Trial: NCT03158831
Drug: Placebo-Controlled Graded Drug Challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.
Trial: NCT00016354
Drug: benzoylphenylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00320099
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg as iv bolus every 6 hours for 7 days
Trial: NCT00320099
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: hydrocortisone 50mg q6 for 7 days
Trial: NCT02625779
Drug: Valproate and Creatine-containing Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02740270
Drug: GWN323
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02740270
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04046939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo twice daily oral dosing for up to 12 weeks
Trial: NCT01498861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a tablet with no drug in it
Trial: NCT03553238
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
Trial: NCT02987738
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two administrations in the evening and 12 hours later
Trial: NCT02247128
Drug: OAC + clopicogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00542178
Drug: Hypoglycemic Agents
RxNorm normalized name: HYPOGLYCEMIC AGENTS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
Trial: NCT00542178
Drug: Standard glycemia control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A strategy of glycemia drugs for HbA1c 7% - 7.9%
Trial: NCT00542178
Drug: Intensive BP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
Trial: NCT00542178
Drug: Standard BP control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A strategy of BP drugs for SBP less than 140 mm Hg
Trial: NCT00542178
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20-40 mg/d
Trial: NCT00542178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01590173
Drug: COH for IVF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both GnRH agonists (long, starting at day 2 or 21) with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany) and antagonists' with ganirelix 0.25 mg (Orgalutran; Organon, Oss, The Netherlands) or cetrorelix 0.25 mg (Cetrotide; Serono, Rome, Italy) protocols will be used; for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the hCG triggering and for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied.
Trial: NCT01527994
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral pill- inactive compound
Trial: NCT02203643
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03553238
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be added to consolidation module of PDT-ETP-ALL protocol.
Trial: NCT01067430
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated tablet, 90 mg taken once a day for 14 days
Trial: NCT01067430
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enteric coated tablet 50 mg given three times a day for 14 days